Key Points BioLineRx and Hemispherian will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia. Both presentations are scheduled for November…
September 24, 2026
From Hypothesis to Reimbursement: The Cancer Research That Reached Patients in 2026
Research institutions and cancer charities mark World Cancer Research Day every September 24, a designation built on one argument: cancer science needs sustained funding. That…
BioLineRx Ltd. (NASDAQ: BLRX) and Hemispherian AS have highlighted new preclinical data suggesting that their drug candidate GLIX1 may significantly boost the effectiveness of PARP…
Northwest Biotherapeutics Inc. (OTCQB: NWBO) is highlighting updated survival data from its Phase III trial of DCVax-L in glioblastoma that underline a key point: more…